Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DiaKine Therapeutics has announced that its developmental drug Lisofylline, significantly reduced indicators of inflammation in visceral fat tissue that are predictive of heart disease and diabetes risk, in a preclinical study.
Subscribe to our email newsletter
The research conducted at the University of Virginia, showed that mice fed on a heavy fat content diet developed the inflammatory markers for heart disease and diabetes. Mice treated with Lisofylline (LSF) had responses that were similar to normal, low-fat diet fed mice. LSF is a drug designed to control selected inflammatory responses of the body that have been linked to cardiovascular disease and diabetes.
LSF, being developed by DiaKine is a synthetic small molecule with novel anti-inflammatory properties. LSF has been shown to reduce interleukin 12 (IL12) signaling and STAT4 activation in target cells and tissues, important pathways linked to inflammation and immune damage to insulin producing cells.
Jerry Nadler, chief science officer of DiaKine, said: “This study suggests that medications with the actions of LSF could reduce inflammation and insulin resistance associated with central obesity – therefore providing a novel opportunity to treat heart disease and prevent type 2 diabetes development.”